Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2022-01-27 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于回购公司股份方案及回购报告书的补充更正公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company regarding a correction to a previously published announcement about its share repurchase plan and related insider trading disclosures. It details transactions by directors and major shareholders, clarifies the absence of insider trading or market manipulation, and states no current or future plans for share changes during the repurchase period. The document is short (2034 characters) and serves as a correction notice to prior announcements rather than a full report or financial statement. It focuses on share repurchase activities and insider transactions, which aligns with the category for company buying back or selling its own shares. Therefore, the document is best classified as a Transaction in Own Shares (POS) filing.
2022-01-27 Chinese
关于公司产品获得CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of CE certification for six medical device products. It includes product details and the significance of the certification for market access and competitiveness. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no voting results, no management changes, no legal proceedings, and no mention of any report publication. The document is a regulatory announcement about product certification, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a general regulatory announcement about product certification compliance and market access. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2022-01-27 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from the board of directors of a company regarding the top ten shareholders and top ten unrestricted shareholders before a share repurchase decision. It references a share repurchase plan and provides detailed shareholding information. This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. The document is short (1331 characters) and contains specific shareholding data related to a repurchase, not a general report or announcement of a report publication. Therefore, it is classified as POS with high confidence.
2022-01-21 Chinese
关于首次实施回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first implementation of a share repurchase program. It details the number of shares repurchased, prices, compliance with regulatory guidelines, and the purpose of the repurchase (employee stock plan or equity incentives). The document is short (1304 characters) and focuses on the share buyback activity rather than financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2022-01-21 Chinese
关于获得发明专利证书的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement from a company about receiving an invention patent certificate. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, no meeting materials, no voting results, no management changes, no capital or financing updates, and no legal proceedings. It is a regulatory announcement about intellectual property rights. Given the short length (572 characters) and the nature of the content, it does not fit into any financial report category but is a general regulatory announcement. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-01-19 Chinese
关于公司第五届董事会第十次临时会议相关事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent directors' opinion on a share repurchase plan discussed at a board meeting. It references compliance with laws and regulations related to share buybacks and confirms the legality and rationale of the repurchase. There are no financial statements or detailed financial data presented, and the document is a formal opinion rather than a report or announcement of voting results. This fits the category of a Transaction in Own Shares (POS) filing, which covers company buyback activities.
2022-01-19 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.